Tolerance to alloantigens remains the single most important issue in marrow transplantation. The overall objectives of this program project are the following: 1) to develop novel strategies for influencing the induction of tolerance in bone marrow transplant (BMT) recipients; 2) to test potential interventions which selectively modulate the host and donor immune response to alloantigens; and 3) to apply the most promising interventions to human in utero and ex utero BMT. Engraftment tolerance will be studied in in utero transplant experiments in which the fetal recipient is relatively immunoincompetent. GVHD tolerance will be studied in patients who are recipients of haplocompatible T-cell depleted BMT. The studies to be conducted include the following: 1) development of anti-sense RNA molecules to induce down regulation of HLA expression; 2) measurement of soluble HLA antigens in patients undergoing BMT and the development of synthetic peptides which can block T-cell mediated cytoxicity 3) development of in vivo interventions in a murine model which can expand the time in gestation when the fetus is susceptible to engraftment of allogeneic cells; 4) characterization of a nonhuman primate model of in utero BMT which will assess the effect of anti T-cell monoclonal antibody in enhancing engraftment of mismatched marrow cells; 5) assessment of tolerance and immune reconstitution in patients undergoing haplocompatible BMT for severe combined immunodeficiency disease (SCID) or leukemia and the assessment of the efficacy of in utero BMT for children with hemoglobinopathies and SCID. These studies will substantially increase the number of patients who could benefit from BMT, and reduce the morbidity, mortality and the cost of marrow transplantation as well as impact on transplantation of solid tissue grafts.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI029512-02
Application #
3092050
Study Section
Special Emphasis Panel (SRC (60))
Project Start
1990-08-01
Project End
1995-07-31
Budget Start
1991-08-01
Budget End
1992-07-31
Support Year
2
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Cowan, M J; Chou, S H; Tarantal, A F (2001) Tolerance induction post in utero stem cell transplantation. Ernst Schering Res Found Workshop :145-71
Carrier, E; Lee, T H; Busch, M P et al. (1997) Recruitment of engrafted donor cells postnatally into the blood with cytokines after in utero transplantation in mice. Transplantation 64:627-33
Mychaliska, G B; Rice, H E; Tarantal, A F et al. (1997) In utero hematopoietic stem cell transplants prolong survival of postnatal kidney transplantation in monkeys. J Pediatr Surg 32:976-81
Kline, R M; Stiehm, E R; Cowan, M J (1996) Bone marrow 'boosts' following T cell-depleted haploidentical bone marrow transplantation. Bone Marrow Transplant 17:543-8
Sorof, J M; Koerper, M A; Portale, A A et al. (1995) Renal transplantation without chronic immunosuppression after T cell-depleted, HLA-mismatched bone marrow transplantation. Transplantation 59:1633-5
Carrier, E; Lee, T H; Busch, M P et al. (1995) Induction of tolerance in nondefective mice after in utero transplantation of major histocompatibility complex-mismatched fetal hematopoietic stem cells. Blood 86:4681-90
Elder, M E; Hope, T J; Parslow, T G et al. (1995) Severe combined immunodeficiency with absence of peripheral blood CD8+ T cells due to ZAP-70 deficiency. Cell Immunol 165:110-7
Cowan, M J; Golbus, M (1994) In utero hematopoietic stem cell transplants for inherited diseases. Am J Pediatr Hematol Oncol 16:35-42
Dror, Y; Gallagher, R; Wara, D W et al. (1993) Immune reconstitution in severe combined immunodeficiency disease after lectin-treated, T-cell-depleted haplocompatible bone marrow transplantation. Blood 81:2021-30